EUCTR2008-004936-19-ES进行中（未招募）1 期
Estudio de fase 2, multicéntrico, en abierto, para evaluar la seguridad y la eficacia del IMC-1121B en combinación con 5-FU/AF y oxaliplatino (FOLFOX-6 modificado) como tratamiento de primera línea en pacientes con cáncer colorrectal metastásico.An Open Label, Multicenter, Phase 2 Study Evaluating the Safety and Efficacy of IMC-1121B in Combination with 5-FU/FA and Oxaliplatin (Modified FOLFOX-6) as First-line Therapy in Patients with Metastatic Colorectal Cancer.
ImClone Systems Incorporated0 个研究点目标入组 45 人开始时间: 2008年11月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The patient must have histologically-confirmed adenocarcinoma of the colon or rectum that is locally-advanced or metastatic und unresectable.
- •The patient has at least one unidimensionally-measurable target lesion (= 2 cm with conventional techniques or = 1 cm with spiral computed tomography [CT] scan or magnetic resonance imaging [MRI], as defined by Response Evaluation Criteria in Solid Tumors [RECIST], see Section 11); target lesion(s) must not lie within an irradiated area.. Patients with locally advanced rectal carcinoma who have undergone previous radiation must have documented evidence of disease progression in the pelvis in order to participate.
- •The patient is age = 18 years.
- •The patient has a life expectancy of = 6 months.
- •The patient has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1 at study entry.
- •The patient has adequate hematologic function, as evidenced by an absolute neutrophil count (ANC) = 1500/µL, hemoglobin = 10g/dL, and platelets =100,000/µL.
- •The patient has adequate hepatic function as defined by: total bilirubin = 1.5 x upper limit of normal (ULN), aspartate transaminase (AST) and alanine transaminase (ALT) = 3.0 x ULN [or 5.0 x ULN in the case of liver metastases], and serum albumin = lower limit of normal institutional range (LLN) or (if < LLN) within 10% of the LLN.
- •The patient has adequate renal function as defined by a serum creatinine = 1.5 x ULN, or creatinine clearance (measured via 24-hour urine collection) = 60 mL/min.
- •The patient's urinary protein = 1+ on dipstick or routine urinalysis ([UA]; if urine dipstick or routine urinalysis is = 2+, a 24 hour urine for protein must demonstrate < 1000 mg of protein in 24 hours to allow participation in the study).
- •The patient must have adequate coagulation function as defined by International Normalized Ratio (INR) = 1.5 and a partial thromboplastin time (PTT) = 5 seconds above the ULN. Patients on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight (LMW) heparin and if on warfarin, must have an INR between 2 and 3 and no active bleeding or pathological condition present that carries a high risk of bleeding (eg, tumor involving major vessels or known varices).
- •The patient has resolution to Grade = 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version3 (NCI-CTCAE v 3.0) of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy with the exception of peripheral neuropathy which must have resolved to Grade 0.
- •The patient agrees to use adequate contraception during the study period and for 8 weeks after the last dose of study treatment.
- •The patient has provided signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The patient has received prior systemic chemotherapy for locally-advanced unresectable or metastatic CRC. Prior adjuvant chemotherapy is allowed if disease progression has been documented > 6 months after the end of the last cycle of adjuvant chemotherapy or > 12 months after the end of the last cycle of adjuvant oxaliplatin-containing regimens.
- •The patient has documented and/or symptomatic brain or leptomeningeal metastases.
- •The patient has participated in clinical studies of nonapproved experimental agents or procedures within 12 weeks of study entry.
- •The patient has received previous therapy with monoclonal antibodies.
- •The patient has received previous therapy with any agent that targets VEGF or VEGFR-2 (including multi-targeted tyrosine kinase inhibitors).
- •The patient has an ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders in the opinion of the investigator.
- •The patient is on chronic nontopical corticosteroid treatment for > 6 months at doses > 10 mg/day of prednisolone or equivalent before study entry, which in the opinion of the investigator could compromise the patient or the study.
- •The patient has a known dihydropyrimidine dehydrogenase (DPD) deficiency.
- •The patient has a known allergy to any of the treatment components.
- •The patient has an acute or subacute intestinal obstruction.
- •The patient has uncontrolled or poorly controlled hypertension on a standard regimen of anti-hypertensive therapy.
- •The patient has a concurrent active malignancy other than adequately treated nonmelanomatous skin cancer, other noninvasive carcinoma, or in situ neoplasm. A patient with previous history of malignancy is eligible, provided that he/she has been disease free for > 3 years.
- •The patient, if female, is pregnant (confirmed by serum beta human chorionic gonadotropin [ßHCG] test) or lactating.
- •The patient has received a prior autologus or allogeneic organ or tissue transplantation.
- •The patient has interstitial pneumonia or interstitial fibrosis of the lung, which in the opinion of the investigator could compromise the patient or the study.
- •The patient has pleural effusion or ascites that causes >Grade 1 dyspnea.
- •The patient has psychological, familial, sociological, or geographical conditions which do not permit adequate study follow-up, compliance with the protocol, or signature of Informed Consent.
- •The patient has undergone major surgery within 28 days prior to the first dose of study medication, or subcutaneous venous access device placement within 7 days prior to the first dose of study medication.
研究者
相似试验
进行中（未招募）
不适用
Estudio de fase II, abierto y multicéntrico para evaluar la eficacia y seguridad de la combinación de panitumumab con irinotecán en pacientes con cáncer colorrectal metastásico con KRAS no mutado y refractario a la quimioterapia basada en irinotecán.Open, multicenter phase II study to evaluate the efficacy and safety of the combination of Panitumumab with Irinotecan in patients with Wild-Type KRAS metastatic colorectal cancer refractory to irinotecan based chemotherapy - SPECTRACáncer colorrectal metastástasico KRAS no mutado y refractarios a la quimioterápia basada en irinotecánEUCTR2009-010833-27-ESGrupo de Tratamiento de los Tumores Digestivos - TTD
进行中（未招募）
不适用
Estudio en fase II, abierto, multicéntrico, prospectivo y aleatorizado, con DTIC o la combinación de Gemcitabina y DTIC en sarcomas de partes blandas avanzados del adultoEUCTR2005-001709-24-ESGrupo Español de Investigación en Sarcomas (GEIS)
进行中（未招募）
不适用
Estudio fase II, multicéntrico, abierto, para comparar la eficacia y seguridad de RAD001 en primera línea seguido de sunitinib en segunda línea frente a sunitinib en primera línea seguido de RAD001 en segunda línea en el tratamiento de pacientes con carcinoma de células renales metastásicoCarcinoma de células renalesMedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2009-011056-21-ESovartis Farmacéutica, S.A427
进行中（未招募）
1 期
Estudio en fase II, abierto, multicéntrico y aleatorizado de RO5083945 en combinación con FOLFIRI frente a FOLFIRI más cetuximab o FOLFIRI en monoterapia como tratamiento de segunda línea en pacientes con cáncer colorrectal metastásico con KRAS natural o mutado. A randomized, multicenter, open-label phase II study of RO5083945 in combination with FOLFIRI versus FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with KRAS wild-type or mutant metastatic colorectal cancer .Cáncer colorrectal metastásico con o sin mutación de gen KRAS y con progresión de la enfermedad tras un tratamiento de primera línea mediante un régimen con oxaliplatino. Metastatic colorectal cancer, KRAS wild-type (WT) or mutant, with disease progression after first line treatment with an oxaliplatin-containing regimen.MedDRA version: 12.1Level: LLTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2010-022983-11-ESF. Hoffmann-La Roche Ltd.169
进行中（未招募）
不适用
Estudio fase II, multicéntrico, abierto, con un grupo de tratamiento, para evaluar la eficacia y la seguridad de AUY922 en combinación con la terapia estándar, trastuzumab, como tratamiento de segunda línea en pacientes con cáncer gástrico avanzado HER2 positivoPacientes con cáncer gástrico avanzado HER2 positivo documentado, que progresen después de observarse beneficio clínico con el tratamiento de 1ª línea con un tratamiento que contenga trastuzumab. El beneficio clínico se define como respuesta global o enfermedad estable de por lo menos 12 semanas de duración, desde el inicio de la terapia de 1ª línea con trastuzumab según RECIST.MedDRA version: 14.0Level: LLTClassification code 10066896Term: HER-2 positive gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002570-23-ESovartis Farmaceutica S.A.48